{"id":"https://openalex.org/W2107095942","doi":"https://doi.org/10.1096/fj.03-0078fje","title":"The importance of propargylamine moiety in the anti\u2010 Parkinson drug rasagiline and its derivatives for MAPK\u2010 dependent amyloid precursor protein processing","display_name":"The importance of propargylamine moiety in the anti\u2010 Parkinson drug rasagiline and its derivatives for MAPK\u2010 dependent amyloid precursor protein processing","alternate_titles":[],"publication_year":2003,"publication_date":"2003-10-02","ids":{"openalex":"https://openalex.org/W2107095942","doi":"https://doi.org/10.1096/fj.03-0078fje","mag":"2107095942","pmid":"https://pubmed.ncbi.nlm.nih.gov/14525944"},"language":"en","primary_location":{"id":"doi:10.1096/fj.03-0078fje","doi":"https://doi.org/10.1096/fj.03-0078fje","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fj.03-0078fje","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2107095942"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5012715564","display_name":"Merav Yogev\u2010Falach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I174306211","display_name":"Technion \u2013 Israel Institute of Technology","ror":"https://ror.org/03qryx823","country_code":"IL","type":"education","lineage":["https://openalex.org/I174306211"]}],"countries":["IL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Merav Yogev-Falach","raw_affiliation_strings":["Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel","institution_ids":["https://openalex.org/I174306211"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005030965","display_name":"Tamar Amit","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I174306211","display_name":"Technion \u2013 Israel Institute of Technology","ror":"https://ror.org/03qryx823","country_code":"IL","type":"education","lineage":["https://openalex.org/I174306211"]}],"countries":["IL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Tamar Amit","raw_affiliation_strings":["Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel","institution_ids":["https://openalex.org/I174306211"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000909905","display_name":"Orit Bar\u2010Am","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I174306211","display_name":"Technion \u2013 Israel Institute of Technology","ror":"https://ror.org/03qryx823","country_code":"IL","type":"education","lineage":["https://openalex.org/I174306211"]}],"countries":["IL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Orit Bar-Am","raw_affiliation_strings":["Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel","institution_ids":["https://openalex.org/I174306211"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053858269","display_name":"Moussa B. H. Youdim","orcid":"https://orcid.org/0000-0002-1361-3872","observed_orcids":["https://orcid.org/0000-0002-1361-3872"]},"institutions":[{"id":"https://openalex.org/I174306211","display_name":"Technion \u2013 Israel Institute of Technology","ror":"https://ror.org/03qryx823","country_code":"IL","type":"education","lineage":["https://openalex.org/I174306211"]}],"countries":["IL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Moussa B.H. Youdim","raw_affiliation_strings":["Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Technion\u2010Faculty of Medicine Eve Topf and NPF Centers for Neurodegenerative Diseases Department of Pharmacology Haifa Israel","institution_ids":["https://openalex.org/I174306211"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I174306211"],"apc_list":{"value":3740,"currency":"USD","value_usd":3740},"apc_paid":null,"fwci":3.0251,"has_fulltext":false,"cited_by_count":121,"citation_normalized_percentile":{"value":0.92456865,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"17","issue":"15","first_page":"2325","last_page":"2327"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rasagiline","display_name":"rasagiline","score":0.9990000128746033},{"id":"https://openalex.org/keywords/propargylamines","display_name":"propargylamines","score":0.8859999775886536},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.9559999704360962},{"id":"https://openalex.org/keywords/app-processing","display_name":"APP processing","score":0.8619999885559082},{"id":"https://openalex.org/keywords/alpha-secretase","display_name":"alpha-secretase","score":0.890999972820282},{"id":"https://openalex.org/keywords/amyloid-beta-toxicity","display_name":"amyloid-beta toxicity","score":0.7829999923706055},{"id":"https://openalex.org/keywords/monoamine-oxidase-b-inhibition","display_name":"monoamine oxidase B inhibition","score":0.8539999723434448},{"id":"https://openalex.org/keywords/structure-activity-relationship","display_name":"structure-activity relationship","score":0.902999997138977},{"id":"https://openalex.org/keywords/pc12-cells","display_name":"PC12 cells","score":0.7540000081062317},{"id":"https://openalex.org/keywords/sh-sy5y-cells","display_name":"SH-SY5Y cells","score":0.8949999809265137},{"id":"https://openalex.org/keywords/neuroprotection","display_name":"neuroprotection","score":0.6850000023841858}],"concepts":[{"id":"https://openalex.org/C2781249495","wikidata":"https://www.wikidata.org/wiki/Q420685","display_name":"Rasagiline","level":4,"score":0.8713467121124268},{"id":"https://openalex.org/C2776568683","wikidata":"https://www.wikidata.org/wiki/Q23005640","display_name":"Moiety","level":2,"score":0.7190983891487122},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5564838647842407},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5206714868545532},{"id":"https://openalex.org/C31705614","wikidata":"https://www.wikidata.org/wiki/Q423510","display_name":"Amyloid precursor protein","level":4,"score":0.4922570288181305},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44817131757736206},{"id":"https://openalex.org/C2777633098","wikidata":"https://www.wikidata.org/wiki/Q2736051","display_name":"Amyloid (mycology)","level":2,"score":0.4390653967857361},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.43379127979278564},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.42669740319252014},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26378604769706726},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.25881797075271606},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13152259588241577},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.11946031451225281},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.10467422008514404},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.10383793711662292},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0610353946685791},{"id":"https://openalex.org/C179104552","wikidata":"https://www.wikidata.org/wiki/Q11165","display_name":"Inorganic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007189","descriptor_name":"Indans","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010293","descriptor_name":"Pargyline","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D010293","descriptor_name":"Pargyline","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D010446","descriptor_name":"Peptide Fragments","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D011437","descriptor_name":"Propylamines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011499","descriptor_name":"Protein Processing, Post-Translational","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D016564","descriptor_name":"Amyloid beta-Protein Precursor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D016716","descriptor_name":"PC12 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D020928","descriptor_name":"Mitogen-Activated Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D020935","descriptor_name":"MAP Kinase Signaling System","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1096/fj.03-0078fje","doi":"https://doi.org/10.1096/fj.03-0078fje","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fj.03-0078fje","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"},{"id":"pmid:14525944","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14525944","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9537000060081482,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320306430","display_name":"National Parkinson Foundation","ror":"https://ror.org/005aa3k38"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W166705661","https://openalex.org/W187181932","https://openalex.org/W1243285799","https://openalex.org/W1491014419","https://openalex.org/W1504283291","https://openalex.org/W1510308646","https://openalex.org/W1526193826","https://openalex.org/W1551782890","https://openalex.org/W1563482732","https://openalex.org/W1964749901","https://openalex.org/W1979710386","https://openalex.org/W1980749733","https://openalex.org/W1981657815","https://openalex.org/W1993964261","https://openalex.org/W1999676188","https://openalex.org/W2003423434","https://openalex.org/W2005056819","https://openalex.org/W2006239462","https://openalex.org/W2007133768","https://openalex.org/W2016232776","https://openalex.org/W2016833889","https://openalex.org/W2024673430","https://openalex.org/W2033592766","https://openalex.org/W2042571235","https://openalex.org/W2044368552","https://openalex.org/W2057005933","https://openalex.org/W2061922599","https://openalex.org/W2064247543","https://openalex.org/W2082953267","https://openalex.org/W2084155803","https://openalex.org/W2084724753","https://openalex.org/W2084962301","https://openalex.org/W2085895924","https://openalex.org/W2090496922","https://openalex.org/W2091558615","https://openalex.org/W2101077392","https://openalex.org/W2113434206","https://openalex.org/W2127061690","https://openalex.org/W2171607869","https://openalex.org/W2302113434","https://openalex.org/W2419056937"],"related_works":["https://openalex.org/W2076097603","https://openalex.org/W95536056","https://openalex.org/W2039437431","https://openalex.org/W1969617718","https://openalex.org/W1550032904","https://openalex.org/W1979710386","https://openalex.org/W1974352826","https://openalex.org/W2149555922","https://openalex.org/W2091558615","https://openalex.org/W2018792227"],"abstract_inverted_index":{"Rasagiline":[0],"[N-propargyl-(1R)-aminoindan]":[1],"a":[2,17,188],"highly":[3],"potent":[4],"selective":[5],"irreversible":[6],"monoamine":[7],"oxidase":[8],"(MAO)-B":[9],"inhibitor":[10,99],"exerts":[11],"neuroprotective":[12],"and":[13,24,27,47,82,91,127,145,155,224,235],"antiapoptotic":[14],"effects":[15],"against":[16,55],"variety":[18],"of":[19,68,73,87,121,143,163,167,208,222,233],"insults":[20],"in":[21,25,212],"cell":[22],"cultures":[23],"vivo":[26],"has":[28],"finished":[29],"its":[30,168,236],"phase":[31],"III":[32],"clinical":[33],"trials":[34],"for":[35,190],"Parkinson's":[36],"disease.":[37],"In":[38,59,197],"the":[39,66,69,74,95,105,119,141,161,205,209,220],"present":[40],"study,":[41],"we":[42,177],"show":[43],"that":[44,104,183,232],"rasagiline":[45,61,135,164,234],"(1":[46],"10":[48],"microM)":[49,139,154],"significantly":[50,62,116,218],"protected":[51],"rat":[52],"PC12":[53,83],"cells":[54],"beta-amyloid":[56],"(Abeta1-42)":[57],"toxicity.":[58],"addition,":[60,198],"increased":[63,140,225],"(approximately":[64],"threefold)":[65],"secretion":[67,221],"nonamyloidogenic":[70],"soluble":[71],"form":[72],"amyloid":[75],"precursor":[76],"protein":[77,122,130],"(sAPPalpha)":[78],"from":[79],"SH-SY5Y":[80],"neuroblastoma":[81],"cells.":[84],"The":[85],"increase":[86],"sAPPalpha":[88,113,223],"was":[89,92,115,149],"dose-dependent":[90],"blocked":[93],"by":[94,118,151],"hydroxamic":[96],"acid-based":[97],"metalloprotease":[98],"Ro31-9790":[100],"(100":[101],"microM),":[102],"suggesting":[103],"effect":[106],"is":[107,172,186],"mediated":[108],"via":[109],"alpha-secretase":[110],"activity.":[111],"Rasagiline-induced":[112],"release":[114,193],"reduced":[117],"inhibitors":[120],"kinase":[123,131],"C":[124],"(PKC),":[125],"GF109203X,":[126],"ERK":[128,195],"mitogen-activated":[129],"(MAPK)":[132],"PD98059.":[133],"Moreover,":[134],"dose":[136],"dependently":[137],"(0.1-10":[138],"phosphorylation":[142,227],"p44":[144],"p42":[146],"MAPK,":[147],"which":[148,171],"abolished":[150],"PD98059":[152],"(30":[153],"GF109203X":[156],"(2.5":[157],"microM).":[158],"By":[159],"comparing":[160],"actions":[162],"with":[165,228],"those":[166],"S-isomer":[169],"TVP1022,":[170],"not":[173,187],"an":[174],"MAO":[175],"inhibitor,":[176],"have":[178],"been":[179],"able":[180],"to":[181,231],"demonstrate":[182],"MAO-B":[184],"inhibition":[185],"prerequisite":[189],"either":[191],"sAPPalpha-induced":[192],"or":[194],"phosphorylation.":[196],"structure-activity":[199],"relationship":[200],"among":[201],"rasagiline-related":[202],"compounds":[203],"suggests":[204],"crucial":[206],"role":[207],"propargyl":[210],"moiety":[211],"these":[213],"molecules,":[214],"because":[215],"propargylamine":[216],"itself":[217],"induced":[219],"MAPK":[226],"similar":[229],"potency":[230],"derivatives.":[237]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2107095942","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
